Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Life tables

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    51 result(s) found for: Life tables. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2009-012275-98 Sponsor Protocol Number: HELENA Start Date*: 2010-09-08
    Sponsor Name:Free state of Bavaria
    Full Title: HEXVIX® VERUS WHITE LIGHT GUIDED TURB FOR EORTC SCORE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWED BY ATTENUATED INTRAVESICAL ADJUVANT CHEMOTHERAPY.
    Medical condition: NON-MUSCLE INVASIVE BLADDER CANCER
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Ongoing)
    Trial results: View results
    EudraCT Number: 2004-000315-26 Sponsor Protocol Number: MO18024 Start Date*: 2004-11-25
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. An Expanded Access Program.
    Medical condition: Metastatic cancer of the colon or rectum.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-003781-40 Sponsor Protocol Number: GCT3014-01 Start Date*: 2021-01-11
    Sponsor Name:Genmab A/S
    Full Title: An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
    Medical condition: Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066481 Hematological malignancy LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) FR (Ongoing) NL (Ongoing) HU (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022413-26 Sponsor Protocol Number: IDEAL-Study Start Date*: 2011-07-29
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (IDEAL-Study)
    Medical condition: Patients in late stage of HIV-infection, treatment naive or without ART for the last 6 month with an acute AIDS-defining illness, namely PCP or TE.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10001509 AIDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003833-14 Sponsor Protocol Number: GOIRC-05-2018 Start Date*: 2019-03-21
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)
    Full Title: A Phase IV study on impact of Edoxaban treatment in Italian cancer patients with venous thromboembolism (EDOI Cancer Study) during antineoplastic therapy
    Medical condition: Venous thromboembolism event associated with cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10066899 Venous thromboembolism LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028997 Neoplasm malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000179-34 Sponsor Protocol Number: P53 Start Date*: 2013-08-28
    Sponsor Name:Maastricht University
    Full Title: More creative on cocaine?
    Medical condition: It is not really a medical condition that is being investigated. The present research proposal has been designed 1) to assess creativity during cocaine intoxication, and 2) to define the potentia...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002117-36 Sponsor Protocol Number: CT-CL02 Start Date*: 2018-11-28
    Sponsor Name:Cristal Therapeutics
    Full Title: A Phase IIa Exploratory Study of CriPec® docetaxel Monotherapy in Subjects with Platinum Resistant Ovarian Cancer.
    Medical condition: Platinum Resistant Ovarian Cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003741-15 Sponsor Protocol Number: MSC_apceth_101/1 Start Date*: 2013-06-27
    Sponsor Name:apceth GmbH & Co. KG
    Full Title: Treatment of Advanced Gastrointestinal Cancer in a Phase I/II trial with modified autologous MSC_apceth_101. Open-label, multicentre, phase I/II.
    Medical condition: Patients suffering from advanced, recurrent or metastatic gastrointestinal adenocarcinoma.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017991 Gastrointestinal neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003353-16 Sponsor Protocol Number: GS-US-339-1559 Start Date*: 2017-04-18
    Sponsor Name:Gilead Sciences, Inc
    Full Title: A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia (AML)
    Medical condition: Acute Myeloid Leukemia (AML)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005490-20 Sponsor Protocol Number: 2002C011G Start Date*: 2016-06-29
    Sponsor Name:ProMetic BioTherapeutics Inc.
    Full Title: A Phase 2/3, Open-Label, Repeat-Dose Study of the Pharmacokinetics, Efficacy, and Safety of ProMetic Plasminogen Intravenous Infusion in Subjects with Hypoplasminogenemia
    Medical condition: Hypoplasminogenemia
    Disease: Version SOC Term Classification Code Term Level
    18.1 10022891 - Investigations 10035493 Plasminogen decreased PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: View results
    EudraCT Number: 2007-005828-32 Sponsor Protocol Number: CECOG/BC 1.3.005 Start Date*: 2008-04-03
    Sponsor Name:CECOG
    Full Title: A randomized phase III 2-arm trial of paclitaxel plus bevacizumab vs. capecitabine plus bevacizumab for the first-line treatment of HER2-negative locally recurrent or metastatic breast cancer
    Medical condition: First-line treatment of patients with locally recurrent or metastatic, HER2-negative breast cancer who have not received prior chemotherapy for locally recurrent or metastatic disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    9.1 10006198 Breast cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) HU (Completed) LV (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-005404-13 Sponsor Protocol Number: CIGE025ADE05 Start Date*: 2007-01-23
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, 24-week, double-blind, placebo-controlled, parallel-group, multicenter study to assess the efficacy and safety of Omalizumab in adult patients with chronic urticaria who exhibit IgE a...
    Medical condition: chronic urticaria
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009159 Chronic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002644-42 Sponsor Protocol Number: DPM-B-305 Start Date*: 2008-07-15
    Sponsor Name:Pharmaxis Pharmaceuticals Limited
    Full Title: A phase III multicenter, randomized, parallel, controlled, double blind study to investigate the safety and efficacy of inhaled mannitol over 12 months in the treatment of bronchiectasis
    Medical condition: Bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006445 Bronchiectasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005836-25 Sponsor Protocol Number: BAY73-4506/15967 Start Date*: 2012-06-12
    Sponsor Name:Bayer HealthCare AG
    Full Title: An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy
    Medical condition: Colorectal neoplasms
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) ES (Completed) GB (Completed) IT (Completed) AT (Completed) NL (Completed) IE (Completed) FR (Completed) PT (Completed) FI (Completed) SE (Completed) GR (Completed) HU (Completed) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-000266-11 Sponsor Protocol Number: 2012-772 Start Date*: 2014-05-27
    Sponsor Name:HOSPICES CIVILS DE LYON
    Full Title: Multicenter, randomized trial of carboplatin +/- paclitaxel in vulnerable elderly patients with stage III-IV advanced ovarian cancer.
    Medical condition: Vulnerable elderly women with newly diagnosed stage III-IV ovarian cancer after an initial debulking surgery or with a planned interval debulking surgery.
    Disease:
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Completed) IE (Completed) DK (Prematurely Ended) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001143-31 Sponsor Protocol Number: CNS-242 Ph2/2 Start Date*: 2005-07-13
    Sponsor Name:Nippon Suisan Kaisha, Ltd
    Full Title: A Phase II, Multicentre, Double-blind, Parallel Group 8 Week Study to Assess the Efficacy and Safety of Two Doses of CNS-242 in Lowering Serum Uric Acid (SUA) and Preventing Gout Attacks in Gout Pa...
    Medical condition: Gout/Hyperuricaemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004460-19 Sponsor Protocol Number: P1604GTN Start Date*: 2017-04-20
    Sponsor Name:G. Pohl-Boskamp GmbH & Co.KG
    Full Title: A multi-centre, randomized, placebo-controlled, double-blind trial to assess the efficacy and safety of nitroglycerin sublingual powder on walking distance in a scheduled forced titration design in...
    Medical condition: Peripheral arterial occlusive disease (PAOD, femoro-popliteal stenosis) and intermittent claudication (Fontaine stage IIb, pain-free walking distance < 200 m), lasting for at least 3 months to ensu...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10074576 Peripheral arterial occlusive disease Fontaine stage IIb LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005462-34 Sponsor Protocol Number: 202006RCT Start Date*: 2021-06-23
    Sponsor Name:Thoraxklinik Heidelberg gGmbH
    Full Title: An open-label, prospective, single centre study of the effects of Riociguat on RIght VEntricular size and function in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
    Medical condition: Symptomatic pulmonary arterial hypertension with a mean pulmonary artery pressure >20 mmHg and pulmonary vascular resistance ≥2 Wood Units, pulmonary arterial wedge pressure ≤15 mmHg (Group I / Nic...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003488-12 Sponsor Protocol Number: 54659 Start Date*: 2016-08-23
    Sponsor Name:University Medical Center Groningen
    Full Title: Efficacy of oral alitretinoin versus oral cyclosporine in patients with moderate to very severe hand eczema. A randomized prospective open-label trial with blinded outcome assessment.
    Medical condition: Hand eczema (HE) is a common condition with a 1-year period prevalence up to 10%. Systemic treatment with alitretinoin is registered for all clinical types of HE. However, it is especially effectiv...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-005095-18 Sponsor Protocol Number: ICR-CTSU/2013/10041 Start Date*: 2014-09-19
    Sponsor Name:The Institute of Cancer Research
    Full Title: A phase II randomised feasibility study of chemoresection and surgical management in low risk non muscle invasive bladder cancer.
    Medical condition: Low risk non muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 21:14:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA